Management of the process of supply of convalescent plasma

For the treatment of coronavirus disease 2019 (COVID-19), health systems have developed disease management strategies. The use of convalescent plasma in patients with severe acute respiratory syndrome (Sars-Cov-2) is recommended. The use of plasma from a donor who has survived COVID-19 is potentially expected to have a good effect.